New Pill Offers Hope Against Pancreatic Cancer

(MENAFN- Investor Brand Network) A new pill can reportedly double survival in early pancreatic cancer trials, raising cautious optimism about a disease that has long resisted treatment. Revolution Medicines' daraxonrasib targets KRAS, a gene that supplies instructions for the development of the K-Ras protein which is essentially a switch for controlling cell division, growth, and death.

The drive to develop new classes of cancer treatments is gaining momentum, and with biomedical firms like Calidi Biotherapeutics Inc. (NYSE American: CLDI) also reaching their own milestones in developing oncolytic virus therapies...

Read More>>

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

MENAFN03062026000224011066ID1111207365